NCT01762878View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 9, 2013

Primary Completion Date

October 21, 2013

Study Completion Date

October 21, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK2269557

Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg

DRUG

Placebo

Dry powder for oral inhalation once daily using DIKUS device

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01762878 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects | Biotech Hunter | Biotech Hunter